Table 1.
Characteristics of all patients in the study and according to pretreatment sPD-1 and sPD-L1 levels.
| Characteristic | All Patients, n (%) |
Low Pretreatment sPD-1, n (%) |
High Pretreatment sPD-1, n (%) |
p Value | Low Pretreatment sPD-L1, n (%) |
High Pretreatment sPD-L1, n (%) |
p Value |
|---|---|---|---|---|---|---|---|
| Total | 121 (100) | 80 (66) | 41 (34) | 40 (50) | 40 (50) | ||
| Median age (range) | 56 (21–65) | 54 (21–65) | 57 (30–65) | 54 (21–65) | 54 (22–65) | ||
| Age | |||||||
| <60 years | 82 (68) | 54 (68) | 28 (68) | 1.000 | 30 (75) | 29 (73) | 0.799 |
| 60–65 years | 39 (32) | 26 (32) | 13 (32) | 10 (25) | 11 (27) | ||
| Gender | |||||||
| Male | 75 (62) | 46 (58) | 29 (71) | 0.172 | 25 (63) | 26 (65) | 0.816 |
| Female | 46 (38) | 34 (42) | 12 (29) | 15 (37) | 14 (35) | ||
| Entity | |||||||
| DLBCL NOS | |||||||
| GCB | 53 (44) | 41 (51) | 12 (29) | 0.055 1 | 18 (45) | 17 (42) | 0.788 1 |
| Non-GCB | 36 (30) | 21 (26) | 15 (37) | 11 (28) | 12 (30) | ||
| ND | 16 (13) | 10 (13) | 6 (15) | 2 (5) | 5 (13) | ||
| Other | 16 (13) | 8 (10) | 8 (19) | 9 (22) | 6 (15) | ||
| ECOG PS | |||||||
| 0–1 | 86 (71) | 60 (75) | 26 (63) | 0.208 | 32 (80) | 20 (50) | 0.005 |
| 2–3 | 35 (29) | 20 (25) | 15 (37) | 8 (20) | 20 (50) | ||
| Stage | |||||||
| 1–2 | 8 (7) | 8 (10) | 0 (0) | 0.050 | 5 (13) | 1 (3) | 0.090 |
| 3–4 | 113 (93) | 72 (90) | 41 (100) | 35 (87) | 39 (98) | ||
| aaIPI score | |||||||
| 0 | 4 (3) | 4 (5) | 0 (0) | 0.341 | 4 (10) | 0 (0) | 0.016 |
| 1 | 6 (5) | 4 (5) | 2 (5) | 2 (5) | 2 (5) | ||
| 2 | 74 (61) | 51 (64) | 23 (56) | 25 (63) | 18 (45) | ||
| 3 | 37 (31) | 21 (26) | 16 (39) | 9 (22) | 20 (50) |
1 Comparing GCB and non-GCB. NOS, not otherwise specified; GCB, germinal center B-cell-like; non-GCB, nongerminal center B-cell-like; ND, not determined; ECOG PS, Eastern Cooperative Oncology Group performance status; aaIPI, age-adjusted International Prognostic Index. The differences in the frequency of prognostic factors in the patient subgroups were compared with chi-square test and the Fisher–Freeman–Halton tests. Statistically significant p-values are bolded.